CEO Richard Twomey leaves Mölnlycke
Richard Twomey, President and CEO of Mölnlycke, will after six years leave the organisation.
"Richard has with his deep knowledge and experience within the medical technology industry developed Mölnlycke into an even stronger company in its field. During his time the company has made significant progress, especially in emerging markets. It has also made big strides in innovation and the establishment of solid clinical evidence and health economics related to our products. Going forward, the strategy remains the same as we are now speeding up the execution phase", says Chairman Gunnar Brock.
"I am proud that I have been able to contribute to the success of Mölnlycke. The company has a solid foundation with a strong product portfolio, very dedicated employees and an owner committed to long term investment in the business", says Richard Twomey.
The search for a new President and CEO is underway and Richard will maintain his current position until he has assisted in the introduction and hand over to his successor.
For further information, please contact Jenny Johansson, Corporate Communications,
+46 739 41 29 23, or jenny.johansson@molnlycke.com
About Mölnlycke
Mölnlycke is a world-leading medical products and solutions company that equips healthcare professionals to achieve the best patient, clinical and economic outcomes. We design and supply products and solutions for use in wound treatment, pressure ulcer and infection prevention and surgery. Our products and solutions provide value for money supported by clinical and health economic evidence.
Mölnlycke employs around 7,800 people and is owned by Investor AB. The company headquarters are in Gothenburg, Sweden and we operate in more than 100 countries worldwide. Since 2007, the company is part of Investor AB, an engaged owner of high-quality, global companies which was founded by the Wallenberg family in 1916. For more information, please visit www.molnlycke.com.
